心通醫療-B(02160.HK):中期錄得淨虧損220萬元
格隆匯8月29日丨心通醫療-B(02160.HK)發佈公告,截至2025年6月30日止六個月,集團錄得收入人民幣2.291億元,同比增加2.7%,主要是由於報告期內,VitaFlow Liberty®及Alwide® Plus在全球商業化的持續推進,促進了集團的海外收入較2024年同期快速增長235.3%。此外,於報告期內,集團的AnchorMan®左心耳封堵系統及AnchorMan®左心耳導引系統在中國的商業化進展穩步推進,且隨後在歐洲實現商業化,亦爲集團帶來新增收入貢獻。
報告期內,集團錄得淨虧損人民幣220萬元,較截至2024年6月30日止六個月的虧損人民幣5780萬元顯著減少,該減少主要是由於(i)收入及毛利穩定增長;(ii)通過持續優化資源配置、積極管控各項費用等措施進一步提升運營效率;及(iii)集團的聯營公司4C Medical完成D輪融資後,視作出售其股權所產生的收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.